New Onset Isolated Granulomatous Dacryoadenitis During Etanercept Therapy

Ocul Immunol Inflamm. 2023 Oct;31(8):1727-1729. doi: 10.1080/09273948.2022.2089687. Epub 2022 Jul 7.

Abstract

Anti-tumor necrosis factor alpha (TNF- α) biological agents can rarely cause sarcoid-like granulomatosis. A 20-year-old woman presented with a 1-month history of painful left upper eyelid swelling. She was on subcutaneous etanercept and methotrexate for 1 year for juvenile idiopathic arthritis. Imaging showed diffuse enlargement of the left and minimal enlargement of the right lacrimal gland. There was no finding in favor of sarcoidosis on systemic evaluation. Incisional biopsy of the left lacrimal gland revealed non-caseating granulomatous dacryoadenitis. The findings showed significant regression 1 month after cessation of Etanercept therapy. To the best of our knowledge, this report illustrates the first case of an isolated granulomatous dacryoadenitis during TNF-α antagonist therapy.

Keywords: Anti- tumor necrosis factor alpha; TNF- α; dacryoadenitis; etanercept; granulomatous dacryoadenitis; lacrimal gland.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dacryocystitis* / chemically induced
  • Dacryocystitis* / diagnosis
  • Dacryocystitis* / drug therapy
  • Etanercept / adverse effects
  • Female
  • Granuloma
  • Humans
  • Lacrimal Apparatus* / pathology
  • Sarcoidosis* / chemically induced
  • Sarcoidosis* / diagnosis
  • Young Adult

Substances

  • Etanercept